LAPK logo
  USC  Laboratory of
  Applied Pharmacokinetics		Some of our members, from left to right: Alan Schumitzky, Michael Van Guilder, Aida Bustad, Roger Jelliffe, David Bayard, Xin Wang, and Mark Milman.

Representative Publications

  1. Peloquin C, Bulpitt A, Jaresko G, Jelliffe R, Childs J, and Nix D: Pharmacokinetics of Ethambutol under Fasting Conditions, with Food, and with Antacids. Antimicrobial Agents and Chemotherapy, 43: 568-572, 1999.

  2. Peloquin C, Bulpitt A, Jaresko G, Jelliffe R, James G, and Nix D: Pharmacokinetics of Pyrazinamide under Fasting Conditions, with Food, and with Antacids. Pharmacotherapy, 18: 1205-1211, 1998.

  3. Corvasier S, Maire P, Bouvier d'Yvoire M, Barbaut X, Bleyzac N, and Jelliffe R: Comparisons between Antimicrobial Pharmacodynamic Indices and Bacterial Killing as Described by Using the Zhi Model. Antimicrobial Agents and Chemotherapy 42: 1731-1737, 1998.

  4. Charpiat B, Falconi I, Breant V, Jelliffe R, Sab J, Ducerf C, Fourcade N, Thomasson A, and Baulieux J: A Population Pharmacokinetic Model of Cyclosporine in the Early Postoperative Phase in Patients with Liver Transplants, and its Predictive Performance with Bayesian Fitting. Ther. Drug Monit. 20: 158-164, 1998.

  5. Jelliffe R, Schumitzky A, Bayard D, Milman M, Van Guilder M, Wang X, Jiang F, Barbaut X, and Maire P: Model-Based, Goal-Oriented, Individualized Drug Therapy: Linkage of Population Modeling, New "Multiple Model" Dosage Design, Bayesian Feedback, and Individualized Target Goals. Clin. Pharmacokinet. 34: 57-77, 1998.

  6. Peloquin C, Jaresko G, Yong C, Keung A, Bulpitt A, and Jelliffe R: Population Pharmacokinetic Modeling of Isoniazid, Rifampin, and Pyrazinamide. Antimicrobial Agents and Chemotherapy 41: 2670-2679, 1997.

  7. Jelliffe R, Gomis P, Tahani B, Ruskin J, and Sattler F: A Population Pharmacokinetic Model of Trimethoprim in Patients with Pneumocystis Pneumonia, made with Parametric and Nonparametric Methods. Ther. Drug Monit. 19: 450-459, 1997.

  8. Breant V, Charpiat B, Sab J, Maire P, and Jelliffe R: How many Patiants and Blood Levels Appear Needed for Population Pharmacokinetic Analysis? A Study with a One - Compartment Model applied to Cyclosporine. Eur. J. Clin. Pharmacol., 51: 283-288, 1996.

  9. Vincent S, Maire P, Bataillard T, Denjean E, Ducrozet P, Laffont A, Visent C, and Jelliffe R: Variabilite Intra-Individuelle des Parametres Pharmacocinetiques de l"Amikacine chez le Sujet Age: Investigations Retrospectives. Pathologie Biologie, 44: 667-674, 1996.

  10. Jelliffe R, Schumitzky A, Bayard D, Milman M, Maire P, Barbaut X, Hurst A, Charpiat B, Breant V, Pivot-Dumarest C, and Tahani B: Terapia Monitorowania: Adaptacyjne metody indywidualizacji dawkowania lekow. Przeglad Podstawowych pojec, odpowiednich zagadnien i niektorych zastowan klinicznych. A five part series translation of Technical Report 94-1, Adaptive Control of Drug Dosage Regimens: an Overview of Basic Concepts, Relevant Issues, and some Clinical Applications, translated by Dr. W. Jawien and Dr. J. Lazowsky.

    11. Part 1 - Farmacja Polska, 52: 339-347, 1996.

    Part 2, ibid., 52: 387-395, 1996,

    Part 3, ibid., 52: 497-508, 1996,

    Part 4, ibid., 52: 554-562, 1996,

    Part 5, ibid., 52: 659-664, 1996.

  11. Maire P, Bleyzac N, Jelliffe RW, and Thalabard J: Theorie de L’adaptation de la Posologie chez le Sujet Age. Act. Pharm. Biol. Clin. 8: 171-182, 1995.

  12. Dodge W, Jelliffe RW, Zwischenberger J, Bellanger R, Hokanson J, and Snodgrass W: Population Pharmacokinetic Models: Effect of Explicit Versus Assumed Constant Serum Concentration Assay Error Patterns upon Parameter Values of Gentamicin in Infants on and off Extracorporeal Membrane Oxygenation. Therapeutic Drug Monit. 16: 552-559,1994.

  13. Neef C, Jelliffe RW, van Laar T, Loohuis T, Essink G, and Janssen E: Comparison of Two Software Programs to be used for the Calculation of Population Pharmacokinetic Parameters. Int. J. Bio-Med. Comput. 36: 143-150, 1994.

  14. Maire P, Barbaut X, Girard P, Mallet A, Jelliffe RW, and Berod T: Preliminary Results of Three Methods for Population Pharmacokinetic Analysis (NONMEM, NPML, NPEM) of Amikacin in Geriatric and General Medicine Patients. Int. J. Bio-Med. Comput. 36: 139-141, 1994.

  15. Maire P, Barbaut X, Vergnaud JM, El Brouzi M, Confesson M, Pivot C, Chuzeville M, Ivanoff N, Brazier JL, and Jelliffe RW: Computation of Drug Concentrations in Endocardial Vegetations in Patients during Antibiotic Therapy. Int. J. Bio-Med. Comput. 36: 77-85. 1994.

  16. Jelliffe RW: Effect of Assumptions Concerning Assay Error Patterns upon Pharmacokinetic Parameter Values and Model Behavior. J. Vet. Pharm. Therap.17: 85-119, 1994.

  17. Confesson MA, Barbaut X, Maire P, Vergnaud JM, El Brouzi A, and Jelliffe RW: Concentrations Calculees d’Aminosides dans des Vegetations d"Endocardites: Relations avec les Pratiques Cliniques lors do Traitement d’Endocardites Infectieuses par l’Amikacin. Therapie, 49: 27-34, 1994.

  18. Charpiat B, Breant V, Dumarest C, Maire P, and Jelliffe RW: Prediction of Future Serum Concentrations with Bayesian Fitted Pharmacokinetic Models: Results with Data Collected by Nurses versus Trained Pharmacy Residents. Therapeutic Drug Monitoring, 16: 166-173, 1994.

  19. Jelliffe RW, Maire P, Sattler F, Gomis P, and Tahani B: Adaptive Control of Drug Dosage Regimens: Basic Foundations, Relevant Issues, and Clinical Examples. Int. J. Biomed. Comput, 36: 1-23, 1994.

  20. Neef C, Jelliffe RW, Laar T van, Loohuis CPPG, Essink AWG, and Jansen ENH: Population Pharmacokinetics of Apomorphine in Patients with Parkinson’s Disease. Drug. Invest. 7: 183-190, 1994.

  21. Confesson M, Barbaut X, Maire P, Vergnaud JM, El Brouzi A, and Jelliffe RW: Concentrations Calculees en Aminoside dans des Vegetations d’Endocardites: Relations avec les Pratiques Cliniques lors du Traitement d’Endocardites Infectieuses par l’Amikacine. Therapie, 49: 27 - 34, 1994.

  22. Grillot M, Maire P, Confesson M, Cogoluhenes V, Pivot C, Druguet M, Courpron P, and Jelliffe RW: Controle Adaptatif des Therapeutiques par l'Amikacine chez des Patients tres Ages: Analyse Retrospective de l’Efficacite et de la Toxicite. Pathologie Biologie, 42: 247-253, 1994.

  23. Maire P, Jelliffe RW, Brazier JL, and Thalabard JC: Pour une Epistemologie de la Pharmacocinetique Clinique, ou: De la Modelisation du Devenir du Medicament dans l’Organisme Humain Considere comme une Machine. in La Philosophe du Remede, ed by Beaune JC. Champ Vallon - PUF, p. 190-201, 1993.

  24. Sittig D, Jiang Z, and Jelliffe RW: A Graphical User Interface to facilitate Patient-Specific Drug Dosing. J. of Medical Systems, 17: 327-333, 1993.

  25. Jelliffe RW, Schumitzky A, Van Guilder M, Liu M, Hu L, Maire P, Gomis P, Barbaut X, and Tahani B: Individualizing Drug Dosage Regimens: The Roles of Population Pharmacokinetic and Dynamic Models, Bayesian Fitting, and Adaptive Control. Therapeutic Drug Monitoring, 15: 380-393, 1993.

  26. Dodge W, Jelliffe RW, Richardson CJ, Bellanger R, Hokanson J, and Snodgrass W: Population Pharmacokinetic Models: Measures of Central Tendency. Drug Invest. 5: 206-211,1993.

  27. Kisor D, Watling S, Zarowitz B, and Jelliffe RW: Population Pharmacokinetics of Gentamicin in Patients with Indicators of Malnutrition: The Use of a New Nonparametric Expectation Maximization (NPEM) Algorithm. Clinical Pharmacokinetics 23: 62-68, 1992.

  28. Maire P, Jelliffe RW, Schumitzky A, and Berod T: Estimation de la Variabilite des Parametres Pharmacocinetiques de l’Amikacine en Pratique Clinique Geriatrique par un Programme Non Parametrique EM de Modelisation en Pharmacocinetique de Population. Pharmacocinetique: de la Recherche a la Clinique. Ed. by Bres J and Panis G., a special issue of the International Journal of Clinical Pharmacy, ISBN 0291-1981. John Libbey Eurotext 1992, pp. 262-267.

  29. Jelliffe RW, Schumitzky A, Van Guilder M: Nonpharmacokinetic Clinical Factors Affecting Aminoglycoside Therapeutic Precision. A Simulation Study. Drug Invest. 4: 20-29, 1992.

  30. Maire PH, Jelliffe RW, Brazier JL, Pozet N, Hadj-Aissa A, Chuzeville M, Druguet M, Courpron P: Drug Therapy in the Elderly: Estimation and Control of Patient Variability. In - Proceedings of the European Society of Clinical Pharmacy Meeting, Poznan, Poland, October 23-26, 1991. in Proceedings of the 20th European Symposium on Clinical Pharmacy, ed by Lazowski J, Jankowiak M, Muller N, Sado P, and Walker R, ESCP Publications, 1992, pp 9-21, ISBN 90-74383-02-5, JM Publishing House, Poznan, Poland.

  31. Jelliffe RW, Iglesias T, Hurst AK, Food KA, and Rodriguez J: Individualising Gentamicin Dosage Regimens: A Comparative Review of Selected Models, Data Fitting Methods, and Monitoring Strategies. Clinical Pharmacokinetics 21: 461-478, 1991.

  32. Dodge W, Jelliffe RW, Richardson CJ, McCleery R, Hokanson J, and Snodgrass W: Gentamicin Population Pharmacokinetic Models for Low Birth Weight Infants, using a New Nonparametric Algorithm. Clinical Pharmacol Therap 50: 25-31, 1991.

  33. Hurst AK, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC: Application of a Bayesian Method to Monitor and Adjust Vancomycin Dosage Regimens: Antimicrobial Agents and Chemotherapy 34:1165-1171, 1990.

  34. Jelliffe RW: Explicit Determination of Laboratory Assay Error Patterns - A Useful Aid in Therapeutic Drug Monitoring (TDM). Check Sample Series: Drug Monitoring and Toxicology, American Society of Clinical Pathologists, Chicago, Il, pp.1-5, 1990.

  35. Jelliffe RW and Schumitzky A: Modeling, Adaptive Control, and Optimal Drug Therapy. Medical Progress through Technology, 16:95-220, 1990.

  36. Maire, P, Jelliffe RW, Dumarest C, Roux D, Breant V, Charpiat B, Vermeulen E, Brazier JL, Courpron P: Controle Adaptatif Optimal des Posologies : Experience des Aminosides en Geriatrie, in Informatique et Sante, ed. by A Venot and P Degoulet, Volume 2, Informatique et Medicaments, Springer-Verlag, Paris, 1989, pp 154-169.

  37. Schumitzky A, Milman M, Khademi P, and Jelliffe RW: Approximate Optimal Closed Loop Control of Pharmacokinetic Systems. Collected papers from a Workshop on "Decision Support for Patient Management: Measurement, Modelling, and Control", London UK, 31st Auigust-2nd September 1989, pp 338-347. Published by the British Medical Informatics Society, London, 1989.

  38. Jelliffe RW: Nuova Cardiologia: Applicazioni del Computer alla Terapia con Farmaci Cardiovascolari (2a Parte). La Cardiologia nel Mondo, 39:413-416, April 1989, Translated by Paolo Ghirardi, M.D.

  39. Jelliffe RW: Nuova Cardiologia: Applicazioni del Computer alla Terapia con Farmaci Cardiovascolari (1a Parte). La Cardiologia nel Mondo, 39:321-324, April 1989. Translated by Paolo Ghirardi, M.D.

  40. Jelliffe RW: Drug-Receptor Relationships, Selection of Therapeutic Goals, and Adaptive Control of Pharmacokinetic Systems. Federation Proceedings, 46(8): 2494-2501, 1987.

  41. Chizeck H, Jelliffe RW, and Cheung P: Guest Editorial, IEEE Transactions on Biomedical Engineering, BME-34, 8:565-566,1987.

  42. Jelliffe RW: Clinical Applications of Pharmacokinetics and Adaptive Control. IEEE Transactions on Biomedical Engineering, BME-34, 8:624-632, 1987.

  43. Hurst AK, Iseri KT, Gill MA, Noguchi JK, Gilman TM, and Jelliffe RW: A Comparison of Different Methods for Predicting Serum Gentamicin Concentrations in Surgical Patients with Perforated and Gangrenous Appendicitis. Clinical Pharmacy, 6:234- 238, 1987.

  44. Marino EL, Dominguez-Gil A, and Jelliffe RW: Control Adaptado de Netilmicina: Regresion Lineal, no Lineal y Estimacion Bayesiana de Parametros Farmacocineticos. Rev Farmacol Clin Exp 3(2):87-92, 1986.

  45. Jelliffe RW: Digitalis Therapy: Simple Formulas to Plan and Adjust Dosage Regimens. M.D. Computing, 1(2):36-41, 1984.

  46. Rodman JH, Jelliffe RW, Kolb E, Tuey DB, deGuzman MF, Wagers PW, and Haywood LJ: Clinical Studies with Computer-Assisted Initial Lidocaine Therapy. Arch Int Med, 144: 703-709, 1984.

  47. Jelliffe RW: "Open-Loop-Feedback" Control of Serum Drug Concentrations. Medical Instrumentation, 17(4): 267-273, 1983.

  48. Jelliffe RW: Computer-Controlled Administration of Cardiovascular Drugs. Progress in Cardiovascular Disease, 26(1): 1-14, 1983.

  49. Marzo A, Ghirardi P, Casagrande C, and Jelliffe RW: The Pharmacokinetic Behavior of SC4453, A New Semisynthetic Cardiac Glycoside, and Digoxin in the Dog. Drugs Expt Clin Res, IX(3): 207-212, 1983.

  50. Jelliffe RW: Pharmacokinetic Dosing Regimens: Implications for Future Technology. AAMI Technology Assessment Report, No. 5: 3-6, 1983.

  51. Rodman JH, Hurst AK, Gaarder T, Cohen J, and Jelliffe RW: Pharmacokinetics and Clinical Response of N-Acetylprocainamide During Multiple Dosing. Clin Pharmacol & Therap, 32(3): 378-386, 1982.

  52. Jelliffe RW: Time-Shared Computer Programs for Therapeutic Drug Monitoring and Adaptive Control of Dosage Regimens, Therapeutic Drug Monitoring Continuing Education and Quality Control Program, American Association for Clinical Chemistry, Washington, D.C., June 1981.

  53. Haldimann B, Healy M, Jelliffe RW, Goldstein D, Pattabhiraman R, and Massry S: Effect of an Oral Dose of 25 - Hydroxyvitamin D3 on its Blood Levels in Patients with the Nephrotic Syndrome. J Clin Endo & Metab 50: 470-474, 1980.

  54. Goicoechea FJ and Jelliffe RW: Computer Programs for Drug Therapy: A Tool for Teaching Pharmacokinetics. Am J Pharm Ed, May 1974, pp 147-152.

  55. Goicoechea FJ and Jelliffe RW: Computerized Dosage Regimens for Highly Toxic Drugs. Am J Hosp Pharm, 31: 67-71, 1974.

  56. Jelliffe RW and Brooker G: A Nomogram for Digoxin Therapy. Am J Med, 57: 63-68, 1974.

  57. Goicoechea FJ, Bischel MD, and Jelliffe RW: Kinetics of Procainamide in Anuric Patients Undergoing Chronic Hemodialysis. Proc Clin Dialysis and Transport Forum, Vol III, 92-95, 1973.

  58. Jelliffe RW: Creatinine Clearance: Bedside Estimate. Ann Int Med, 79: 604-605, 1973.

  59. Jelliffe RW: Quantitative Aspects of Clinical Judgement. Am J Med, 55: 431-433, 1973.

  60. Jelliffe RW, Buell J, and Kalaba R: Reduction of Digitalis Toxicity by Computer-Assisted Glycoside Dosage Regimens. Ann Int Med, 77: 891-906, 1972. Also reprinted in Computer-Assisred Medical Decision Making, ed by Reggia J and Tuhrim S, Springer-Verlag, New York, Volume 1, pp. 93-124, 1985.

  61. Jelliffe RW: New Developments in Drug Dosage Regimens. J Mond Pharm, 15: 53-78, 1972.

  62. Jelliffe RW and Jelliffe SM: Estimation of Creatinine Clearance from Changing Serum Creatinine Levels. Lancet II: p 710, 1971.

  63. Jelliffe RW and Jelliffe SM: A Computer Program for Estimation of Creatinine Clearance from Unstable Serum Creatinine Levels, Age, Sex, and Weight. Math Biosci, 4: 17-24, 1972.

  64. Brooker G and Jelliffe RW: Serum Cardiac Glycoside Assay Based Upon Displacement of 3H Ouabain from Na-K ATPase. Circ, 45: 20-36, 1972.

  65. Jelliffe RW: Nomograms for Gentamicin Dosage. Los Angeles County/USC Medical Center Therapeutic Committee, Drug Bulletin, Volume 5, Number 2, August 1971.

  66. Jelliffe RW: A Nomogram for Kanamycin Dosage. Los Angeles County/USC Medical Center Therapeutics Committee Drug Bulletin, Volume 5, Number 2, August 1971.

  67. Jelliffe RW: Estimation of Creatinine Clearance when Urine Cannot be Collected. Lancet, 1: 975, 1971.

  68. Jelliffe RW: Factors to Consider in Planning Digoxin Therapy. J Chron Dis, 24: 407-416, 1971.

  69. Jelliffe RW: An Improved Method for Replacing One Digitalis Glycoside with Another. Medical Times, 98(1): 105-117, 1970.

  70. Jelliffe RW, Buell J, Kalaba R, Sridhar R, Rockwell RW, and Wagner JG: An Improved Method of Digitoxin Therapy. Ann Int Med, 71: 453-464, 1970.

  71. Jelliffe RW, Buell J, Kalaba R, Sridhar R, and Rockwell R: A Computer Program or Digitalis Dosage Regimens. Math Biosci, 9: 179-193, 1970.

  72. Jelliffe RW, Buell J, Kalaba R, Sridhar R, and Rockwell R: A Mathematical Study of the Metabolic Conversion of Digitoxin to Digoxin in Man. Math Biosci, 6: 387-403, 1970.

  73. Buell J, Jelliffe RW, Kalaba R, and Sridhar R: Modern Control Theory and Optimal Drug Regimens--II: Combination Therapy. Math Biosci, 6: 67-74, 1970.

  74. Buell J, Jelliffe RW, Kalaba R, and Sridhar R: Modern Control Theory and Optimal Drug Regimens--1: The Plateau Effect. Math Biosci, 5: 283-296, 1969.

  75. Jelliffe RW: Therapeutic Guidelines. Administration of Digoxin. Dis Chest, 56: 56 - 60, 1969.

  76. Jelliffe RW, Hill D, Tatter D, and Lewis E, Jr: Death from Weight-Control Pills. A Case Report, with Objective Post-Mortem Confirmation. JAMA, 208: 1843-1847, 1969.

  77. Jelliffe RW and Stephenson RG: A Fluorometric Determination of Myocardial Digoxin at Autopsy. Am J Clin Path, 51(3): 347-357, 1969.

  78. Jelliffe RW: An Improved Method of Digoxin Therapy. Ann Int Med, 69: 703-717, 1968.

  79. Jelliffe RW: A Mathematical Analysis of Digitalis Kinetics in Patients with Normal and Reduced Renal Function. Math Biosci, 1: 305-325, 1967.

  80. Jelliffe RW: An Ultramicro Fluorescent Spray Reagent for Detection and Quantification of Cardiotonic Steroids on Thin-Layer Chromatograms. J Chromatog, 17: 172-179, 1967.

  81. Jelliffe RW: Autopsy Verification of Suicide by Digitalis: A Case Report, with Successful Chemical Identification of Digitalis Glycosides in Gastric Contents. Am J Clin Path, 42(2): 180-185, 1967.

  82. Jelliffe RW: A Chemical Determination of Urinary Digitoxin and Digoxin in Man. J Lab & Clin Med, 67(4): 694-708, 1966.

  83. Jelliffe RW and Blankenhorn DH: Gas Chromatography of Digitoxigenin and Digoxigenin. J Chromatog, 12: 268-270, 1963.
 

  © 2000 - 2008 Laboratory of Applied Pharmacokinetics. All rights reserved.